CD8A and cancer: α-Galactosylceramide is a glycolipid, and dendritic cells that recognize it have been reported to activate NKT cells in the body, leading to induce not only direct cancer cell damage by NKT cells but also gross anti-tumor immunity, including activating CD8+ T cells and NK cells [8,11].